AnodyneWiki

Yohimbine

Yohimbine
Yohimbine
[]
Yohimbine hydrochloride
Generated by the Chemistry Development Kit (http://github.com/cdk)
Molecular structure via molpic based on CDK
[]
Conformer structure via 3Dmol.js
Enable javascript to view conformer structure via 3Dmol.js
Physical properties
[]
354.4 g/mol [1]
Melting point241 °C [1]
Solubility3.48e-01 g/L [1]
2.9 [1]
Structural Identifiers
[]
C21H26N2O3 [1]
methyl (1S,15R,18S,19R,20S)-18-hydroxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate [1]
COC(=O)[C@H]1[C@H](CC[C@@H]2[C@@H]1C[C@H]3C4=C(CCN3C2)C5=CC=CC=C5N4)O [1]
InChI=1S/C21H26N2O3/c1-26-21(25)19-15-10-17-20-14(13-4-2-3-5-16(13)22-20)8-9-23(17)11-12(15)6-7-18(19)24/h2-5,12,15,17-19,22,24H,6-11H2,1H3/t12-,15-,17-,18-,19+/m0/s1 [1]
InChIKeyBLGXFZZNTVWLAY-SCYLSFHTSA-N [1]
Pharmacokinetics[]
Elimination half-life0.25 – 2.5 hours[3]

Yohimbine (also known as Yohimbine, Yohimbin, Quebrachine, Corynine, Quebrachin, APHRODINE, Yohimbic acid methyl ester, Yohimbinum, 17α-hydroxyyohimban-16α-carboxylic acid methyl ester or Dtxsid9040130) is a substance of the β-carboline class.

Chemistry

Salts []

Yohimbine is typically found in the form of its hydrochloride salt.

 []

Yohimbine is a absolute mixture.

Pharmacology

In the () yohimbine acts

Metabolism

Subjective effects []

 []

  • Australia: Yohimbine is a S4 substance.
  • Canada: Yohimbine is a prescription only substance.
  • United States: Yohimbine is a unscheduled substance.

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 8969, Yohimbine. Accessed April 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/8969

  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Yohimbine. UNII: 2Y49VWD90Q. Global Substance Registration System. Accessed April 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/2Y49VWD90Q

  3. Hedner T, Edgar B, Edvinsson L, Hedner J, Persson B, Pettersson A. Yohimbine pharmacokinetics and interaction with the sympathetic nervous system in normal volunteers. European Journal of Clinical Pharmacology. 43(6):651–6.